MVA85A/AERAS-485

BIOLOGICAL2 trials

Sponsors

Aeras

Conditions

HIV InfectionsTuberculosis

Phase 2

A Study of MVA85A in Healthy Infants

CompletedNCT00953927

AerasTuberculosis

Start: 2009-07-31Updated: 2016-05-24

Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)

CompletedNCT01151189

AerasHIV Infections, Tuberculosis

Start: 2011-07-31End: 2014-09-30Updated: 2016-05-24

Related Papers

Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial

PLoS ONE2015-11-1027 citations

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.

2015-02-26121 citations

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.

2014-06-0918 citations

Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects

PLoS ONE2013-06-2813 citations

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.

2013-03-01791 citations